Pipeline
● Conducting US & Korean phase 2 clinical trials for oral mucositis, and planning to enter P2 clinical study for GvHD in 2022.
● Focusing on discovering candidates derived from BIM technology and its non-clinical studies for neurodegenerative diseases.
HNSCC: Head and neck squamous cell carcinoma; HSCT: Hematopoietic stem cell transplantation; GvHD: Graft versus host disease; AD: Alzheimer’s disease; PD: Parkinson’s disease;
FRDA: Friedreich’s Ataxia; NASH: Non-alcoholic steatohepatitis; IPF : Idiopathic pulmonary fibrosis